阿摩線上測驗
登入
阿摩線上測驗
登入
試卷名稱：111年 - 111 消化系內科專科醫師甄審試題#131307
年份：111年
科目：消化系內科專科醫師
75. 關於 HCC systemic therapy 的敘述下列何者正確？
(1) Systemic chemotherapy with doxorubicin or FOLFOX did not demonstrate survival benefits.
(2) Lenvatinib targets VEGFR1-3; fibroblast growth factor receptor (FGFR1-4);
platelet-derived growth factor receptor α, RET, and KIT.
(3) Cabozantinib is a MET, VEGFR2 and RET inhibitor approved for thyroid,renal cancer and HCC.
(4) Ramucirumab is a monoclonal antibody targeting VEGFR 1-3.
(5) Atezolizumab plus cabozantinib showed a superiority to sorafenib in median progression-free survival (PFS).
(A) (1)＋(2)
(B) (1)＋(2)＋(3)
(C) (2)＋(3)＋(4)
(D) (1)＋(2)＋(3)＋(5)
(E) (1)＋(2)＋(3)＋(4)＋(5)
